Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT02969447·Phase 4·INTERVENTIONAL

Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination

OxytocinOtherCompleted

Status

Completed

Phase

Phase 4

Enrollment

27

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Prospective randomized trail which compare 2 regimens for third-stage management after second trimester medical pregnancy termination : 10UI intra venous oxytocin or no additional medication after fetal expulsion. Primary outcome was the incidence of placental retention.

Full detailed description

Complication of third stage of labor in second trimester medical pregnancy termination is not well studied. Accord to publications, the placental retention rate is 30 to 40% in these situations. Placental retention may be associated with increased blood loss, increased requirement for blood transfusion anesthetic and operative complications, and infectious morbidity. The high incidence of retained placenta is an area of clinical concern. Publications reveal a wide variation in practices but there are only few studies about third stage of labor in second trimester medical pregnancy termination. The study is a prospective randomized trial. Two third stage management strategies are compared: 10 units of intra venous oxytocin (group 1) and no additional medication (group 2) after fetal expulsion. It concerns pregnancies between 14 and 28 weeks gestation.

Interventions

Treatment arms and agents.

DRUG

Administration of 10 units of intra venous oxytocin after fetal expulsion

Timeline

From registration to results.

  1. First posted

    Nov 21, 2016

  2. Study start

    Oct 20, 2016

  3. Primary completion

    Aug 4, 2017

  4. Study completion

    Aug 4, 2017

  5. Results posted

    Not reported

  6. Registry updated

    May 12, 2026

Outcomes

What the study measures.

Primary outcomes

Incidence of placental retention

Time frame · Up to 30 minutes after fetal expulsion

Secondary outcomes

Incidence of partial placental retention

Time frame · Up to 1 hour after fetal expulsion

Incidence of digital exploration

Time frame · Up to 1 hour after fetal expulsion

Incidence of blunt curettage

Time frame · Up to 1 hour after fetal expulsion

Incidence of post-partum hemorrhage

Time frame · Up to 1 hour after fetal expulsion

Blood loss

Time frame · Up to 1 hour after fetal expulsion

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * 18 years old and older * medical pregnancy termination between 14 and 28 weeks gestation * informed consent obtained Exclusion Criteria: * less than 18 years old * refusal to consent * in utero fetal death

Study locations

1 registered sites.

France. Showing up to 24 locations stored in the fast local snapshot.

CHU de Bordeaux

Bordeaux, France

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Oxytocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsOxytocin trial dashboard →